Navigation Links
Former Secretary of Veterans Affairs James Peake to Join the Cellphire Board of Directors
Date:6/30/2009

Peake to provide guidance and direction regarding military needs, clinical uses and funding sources

ROCKVILLE, Md., June 30 /PRNewswire/ -- Cellphire, Inc., a biotechnology company located in Rockville, Md., announced today that former Secretary of the Department of Veterans Affairs, James Peake, MD, has joined its board of directors.

"I am excited about the potential of Thrombosomes(R) to save lives on the battlefield and in emergency rooms throughout the US. I am eager to contribute to the effort to conduct appropriate clinical trials to evaluate and ultimately field this product," said Dr. Peake.

Cellphire is committed to developing a freeze-dried platelet product, Thrombosomes(R), which could potentially be effective in stopping uncontrollable bleeding on the battlefield or in trauma. Platelets can only be stored for 5 days and cannot be provided to combat zones, although in-the-field harvesting is being performed. Cellphire's product is expected to have a 12 month shelf life and be immediately available for infusion after adding sterile water.

"We are excited about the addition of Dr. Peake to the Cellphire Board," said Cellphire President Mike Fitzpatrick. "With his incomparable experience and tireless commitment to providing the best possible care for the active duty uniformed services and veterans, we feel sure his contributions will help us achieve our goal."

Dr. Peake is a retired U.S. Army Lieutenant General; he was selected as the U.S. Army Surgeon General. After retirement from the Army he served as the Executive Vice President and Chief Operating Officer of Project Hope and most recently as the Secretary of the U.S. Department of Veterans Affairs. A native of St. Louis and graduate of the U.S. Military Academy at West Point, Peake attended medical school after serving in Vietnam with the 101st Airborne Division, where he was awarded the Silver Star and Purple Heart.

About Cellphire

Cellphire, Inc., a biotechnology company, is focused on developing stabilized cellular materials for advanced technologies in the therapeutic and diagnostic markets. Current efforts and product development are aimed toward stabilized platelets for advanced wound care, transfusion, and reagent products for clinical and research diagnostics.

For more information please visit: http://www.cellphire.com/.


'/>"/>
SOURCE Cellphire, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
2. Former EPA official calls for new environmental and consumer protection agency
3. Cliff Consulting, Inc. Adds Former Banking IT Executive Ashok Moorthy to Its Team
4. Former GE Healthcare Director, Per Foss Appointed CEO for HUNT Biosciences
5. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
6. Lakewood-Amedex, Inc. Appoints William J. Robison, Former Executive Vice President of Pfizer, as Board Member
7. Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise
8. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
9. Former SADMERC Medical Directors Join OrthoCare Innovations as Medical and Scientific Advisory Board Members and Strategic Advisors
10. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
11. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 2017 , ... Ellen Matloff, president and CEO of My ... a 2017 Women of Innovation® finalist. Matloff will be among several women to ... dinner recognizes women accomplished in science, technology, engineering and math (STEM), along with ...
(Date:3/23/2017)... March 23, 2017 In today,s ... equities in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: ... (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market ... free report at: ...
(Date:3/22/2017)... SANTA MONICA, Calif. , March 22, 2017 ... Council (MassMEDIC) are proud to announce their extended partnership ... Week will be headlined by the 21 st ... UBM,s BIOMEDevice Boston, taking place May 3-4, 2017. ... with Advanced Medical Technology Association (ADVAMED) President and ...
(Date:3/22/2017)... , March 22, 2017 MarketNewsUpdates.com ... ... cancer conditions are being pressured as of late due to ... cancer pain management has a dramatic impact on patient,s quality ... and development activities for identifying new forms of opioid formulations ...
Breaking Biology Technology:
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... Recidivism and Reentry. "Too often, too ... prisons and county jails are trying to tackle ... inmates and friends and family members. While significant steps ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
(Date:2/13/2017)... Feb. 13, 2017 Former 9/11 Commission border ... Committee, Janice Kephart of Identity Strategy Partners, ... Donald Trump,s "Executive Order: Protecting the Nation From ... 2017):  "As President Trump,s ,Travel Ban, Executive ... now essentially banned the travel ban, it is important ...
Breaking Biology News(10 mins):